Introduction cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) is a second generation Pt anticancer drug following cis-diamminedichloroplatinum(II)
(cisplatin). It shows the same level of activity as cisplatin in treating some kinds of cancers, but is much less nephrotoxic and emetic than cisplatin (1, 2) . Carboplatin has gained worldwide marketing approval and is currently used as standard therapy in ovarian cancer patients.
Compared with cisplatin, carboplatin causes substantial myelosuppression, principally thrombocytopenia -a dose-limiting side effect that has prompted a continuing search for new, potent Pt complexes possessing lower toxicity. Indeed, the past decade has witnessed a shift in focus toward nonclassical Pt compounds represented by picoplatin, polynuclear complexes, trans-Pt complexes and Pt(IV) complexes (3) . Unfortunately, the outcomes of clinical trials of these complexes have failed to meet expectations, and none of these complexes has been approved for clinical application (4) . However, direct modifi cation of clinically established Pt drugs remains an effective way to create new derivatives with improved toxicological profi les (5, 6 ). 3-Hydroxycarboplatin (Figure 1 ), fi rst reported in 2004 by G. Bernhardt et al. (7) , is a direct and simple derivative of carboplatin in which the cyclobutane ring is substituted with OH at position 3. As part of a drug development programme beginning in 2001 aimed at improving the pharmacological profi le of
3-Hydroxycarboplatin, a Simple Carboplatin Derivative Endowed with an Improved Toxicological Profi le
carboplatin, we designed and prepared a series of carboplatin derivatives, including 3-hydroxycarboplatin. Following extensive biological evaluation, we found that 3-hydroxycarboplatin showed anticancer activity similar to that of carboplatin, but exhibited an improved toxicological profi le, suggesting great promise for further development. In the present article, we report the synthesis, characterisation and biological effects of 3-hydroxycarboplatin in vitro as well as in vivo using two animal models.
Synthesis and Characterisation

Preparation of 3-Hydroxy-1,1-cyclobutanedicarboxylic Acid
3-Hydroxy-1,1-cyclobutanedicarboxylic acid was prepared according to Scheme I in a similar method to that reported earlier (7) with epichlorohydrin as the starting chemical. First, epichlorohydrin was treated with benzyl bromide in the presence of mercuric chloride and heated at 160ºC to give the benzyl ether 5 with a yield of 70%. Then, the addition of diethyl malonate on derivative 5 gave the cyclobutane 6 with 51% yield. The hydrolysis of 6 yielded the potassium salt 7 with 69% yield. Hydrogenolysis was then used for the cleavage of 7 forming the desired 3-hydroxy-1,1-cyclobutanedicarboxylic acid 8 in 60% yield. The overall yield for the formation of 8 was about 15% (melting point 156-158ºC). The product 8 was characterised by elemental analysis and proton nuclear magnetic resonance spectroscopy ( 1 H-NMR), and the data are consistent with its composition and structure and are as reported in the literature (7 In order to further characterise the product, single crystals suitable for X-ray analysis were selected from its zinc salt which was prepared in a two-step procedure. 3-Hydroxy-1,1-cyclobutanedicarboxylic acid was mixed H-NMR spectra are all consistent with the corresponding protons both in the chemical shifts and the number of hydrogens. Two protons of CH 2 split into two bands near 3.27 ppm and 2.55 ppm, probably due to different spatial orientations in a chair confi guration of the cyclobutane ring after the introduction of OH at position 3 (11). The 13 C-NMR spectra conform to the expected carbon chemical shifts in the 3-hydroxycarboplatin molecule.
The Oak Ridge Thermal Ellipsoid Plot (ORTEP) drawing of the complex depicted along with its atomic numbering scheme is shown in Figure 3 and the selected bond distances and bond angles are listed in Table II . The Pt(II) centre has the expected square planar geometry exhibiting the usual structure parameters. The basal square plane is constituted by two NH 3 and two COO -moieties of 3-hydroxy-1,1-cyclobutanedicarboxylate. As shown in Table  II , Pt-N and Pt-O distances and coordinate bond angles of N-Pt-N and O-Pt-O are in the normal range. Similar to the carboplatin molecule (12), the cyclobutane ring adopts a chair configuration and is nearly perpendicular to the Pt(II) coordination plane.
Physicochemical Properties of 3-Hydroxycarboplatin
The solubility of 3-hydroxycarboplatin and carboplatin in water and in octanol was measured at 25ºC ( Table III) . As expected, 3-hydroxycarboplatin is nearly twice as soluble in water as carboplatin. Surprisingly, it is also much more soluble in octanol than carboplatin, probably because the lattice energy is decreased with the reduction in symmetry from C 2v of carboplatin to C s of 3-hydroxycarboplatin (13) . Therefore, 3-hydroxycarboplatin has a more favourable oil/water partition coeffi cient (logP).
The aquation rate constant, which is an important parameter in judging the stability of Pt anticancer compounds, was determined by using a previously reported conductivity method (14) . The observed aquation rate constant (k obs ) of 3-hydroxycarboplatin at 25ºC under an N 2 atmosphere was 2.9 × 10 -6 min -1 , less than k obs of carboplatin (3.8 × 10 -6 min -1 ) under the same conditions, suggesting that 3-hydroxycarboplatin is slightly more stable in water than carboplatin itself. As shown in Table IV , the activity of 3-hydroxycarboplatin against A549, SK-OV-3 and COCI cancer cells was comparable to that of carboplatin. This indicates that introduction of the OH group into carboplatin does not reduce cytotoxicity. 
Biological Evaluation
In Vitro Anticancer Activity
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Acute Toxicity
Acute toxicity is an adverse, non-specifi c effect that occurs in a healthy animal within 2 weeks of intravenous (iv) injection of a single dose of the drug. Acute toxicity tests of 3-hydroxycarboplatin and carboplatin were carried out in healthy Institute of Cancer Research (ICR) mice according to standard procedures (16). Toxicity, measured as the LD 50 value (i.e., the dose that causes the death of 50% of tested animals), was 275 mg kg -1 for 3-hydroxycarboplatin and 148 mg kg -1 for carboplatin, indicating that 3-hydroxycarboplatin is less toxic than carboplatin in animals following iv administration. Histological postmortem examinations of the mice suggested that these Pt complexes caused death primarily through myelosuppression.
Antitumour Activity
The antitumour activity of 3-hydroxycarboplatin and carboplatin was compared in mouse Lewis lung tumour and human ovarian carcinoma (3AO cell line) xenograft models, using well-established methods (15) (16) (17) (18) (19) . Based on previous studies, the maximum tolerated dose (MTD) is 90 mg kg -1 for 3-hydroxycarboplatin and 60 mg kg -1 for carboplatin in mice treated with drugs every three days (Q3D) three times each. Tumour-bearing mice were intravenously given 3-hydroxycarboplatin and carboplatin at the MTD. As shown in Table V , treatment with 3-hydroxcarboplatin following tumour implantation caused a dosedependent reduction of tumour weight in both Lewis lung tumour and 3AO xenograft mice. Notably, the potency of 3-hydroxcarboplatin with respect to inhibition of tumour growth was comparable or superior to that of carboplatin, consistent with the results observed in in vitro cytotoxicity tests.
Myelosuppression Toxicity
To further explore the potential advantage of 3-hydroxycarboplatin over carboplatin, a repeateddosing toxicity study was conducted (20) . ICR mice were iv administered either 3-hydroxycarboplatin or carboplatin on days 1, 3, 5, and 7. On day 8, all mice were anesthetised and blood samples were collected for blood cell analysis; bone marrow cells were also extracted for proliferation tests. Blood cell counts are a good indicator of bone marrow cell proliferation, and thus myelosuppression, a major side effect of carboplatin. The decrease in blood cell counts associated with this myelosuppression is especially prominent for white blood cell and platelet numbers.
As shown in Figures 4-6 , both 3-hydroxycarboplatin and carboplatin exerted myelosuppressive effects, as evidenced by lower blood cell counts compared with the control group. However, the effects were much more pronounced with carboplatin, which caused very severe thrombocytopenia. Consistent with the results of peripheral blood cell counts, mouse bone marrow cell proliferation was suppressed to a much lesser extent by 3-hydroxycarboplatin than by carboplatin (Table VI) . 3-Hydroxycarboplatin at a dose of 60 mg kg -1 did not signifi cantly suppress bone marrow cell proliferation, with myeloproliferation ranging from extremely to moderately active. However, the degree of myeloproliferation was low or extremely low in bone marrow from mice treated with the same dose of carboplatin (60 mg kg -1 ). Collectively, these data indicate that the myelosuppressive side effects of 3-hydroxycarboplatin are much lower than those of carboplatin.
Conclusion
3-Hydroxycarboplatin, a simple carboplatin derivative, shows antitumour activity comparable to that of carboplatin but has much lower toxicity, particularly with respect to myelosuppression, refl ecting an improved toxicological profi le. It also exhibits desirable physicochemical properties. Therefore, 3-hydroxycarboplatin has extremely high potential for development as a clinically useful anticancer agent to replace carboplatin.
